Antios is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases, with a lead program targeting chronic HBV. Its lead candidate, ATI-2173, is a once-daily oral investigational phosphoramidate prodrug of clevudine monophosphate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development. ATI-2173 is in Phase 2b development and is being evaluated in the SAVE-1 trial, a double-blind, randomized, placebo-controlled study of 30 patients testing 25 mg and 50 mg doses daily for 90 days in combination with tenofovir disoproxil fumarate (TDF). Preclinical data and Phase 1b results indicate potent on-treatment and durable off-treatment HBV DNA suppression and that the drug has been generally well-tolerated. The company plans to advance ATI-2173 through Phase 2b and further clinical development toward a potential curative once-daily HBV regimen. The recent $75 million financing strengthens Antios's financial position to support these clinical programs. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases. Its lead candidate, ATI-2173, is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) designed to deliver the 5'-monophosphate of clevudine to the liver. ATI-2173 is described as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site, producing potent antiviral activity and extended off-treatment suppression of HBV DNA. The company plans to advance ATI-2173 through a Phase 2 clinical program to evaluate its potential as the backbone of a once-daily curative regimen for chronic hepatitis B. Antios reported potent on-treatment and durable off-treatment effects in a Phase 1b study, with those results slated for presentation at an upcoming medical conference. To support development, Antios completed a $96 million Series B financing. Antios Therapeutics is an Atlanta, GA–based biopharmaceutical company focused on developing novel antiviral therapies for unmet medical needs. Its lead oral candidate, ATI-2173, is being advanced as part of a curative regimen for chronic hepatitis B virus (HBV) and potentially hepatitis D virus (HDV). The company targets chronic HBV, which affects over 250 million people worldwide and is a leading cause of chronic hepatitis, liver cirrhosis and liver cancer. Antios is led by co-founders Abel De La Rosa (CEO) and Douglas Mayers (CMO). The company intends to use proceeds from its recent financing to continue development of ATI-2173. The article does not disclose revenue or user metrics.

Total raised

$196M

Funding rounds

3

Latest round

Series B

Latest activity

Nov 2021